4 completed. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 4 |
Follow DBV Technologies: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children DBV712 250 mcg - Peanut Allergy | Phase 3 | Completed | DBV Technologies | 304 | 2018-12-06 | 2026-10-28 |
| Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age Part A Viaskin Peanut 250 mcg, Part A Viaskin Peanut 100 mcg, Part A Placebo - Peanut Allergy | Phase 3 | Completed | DBV Technologies | 414 | 2017-07-31 | 2024-12-16 |
| Safety Study of Viaskin Peanut to Treat Peanut Allergy Viaskin Peanut 250 µg, Placebo - Peanut Allergy | Phase 3 | Completed | DBV Technologies | 393 | 2016-10-25 | 2026-10-08 |
| Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy Viaskin Peanut 250mcg, Placebo - Peanut Allergy | Phase 3 | Completed | DBV Technologies | 500 | 2015-12-01 | 2025-06-18 |
United States (4) · Canada (3) · Australia (2) · Germany (2) · Ireland (2) · France (1) · Netherlands (1) · United Kingdom (1)
PMID 37163622, PMID 30794314, PMID 31442495, PMID 32502548, PMID 33259921, PMID 39956162, PMID 40023371, PMID 40204253